ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
70.76
+0.01 (0.01%)
At close: Apr 29, 2025, 4:00 PM
71.00
+0.24 (0.34%)
Pre-market: Apr 30, 2025, 4:01 AM EDT
ANI Pharmaceuticals Revenue
In the year 2024, ANI Pharmaceuticals had annual revenue of $614.38M with 26.20% growth. ANI Pharmaceuticals had revenue of $190.57M in the quarter ending December 31, 2024, with 44.75% growth.
Revenue (ttm)
$614.38M
Revenue Growth
+26.20%
P/S Ratio
2.22
Revenue / Employee
$684,923
Employees
897
Market Cap
1.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 614.38M | 127.56M | 26.20% |
Dec 31, 2023 | 486.82M | 170.43M | 53.87% |
Dec 31, 2022 | 316.39M | 100.25M | 46.38% |
Dec 31, 2021 | 216.14M | 7.66M | 3.67% |
Dec 31, 2020 | 208.48M | 1.93M | 0.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ANIP News
- 20 days ago - ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewsWire
- 4 weeks ago - ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewsWire
- 5 weeks ago - ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewsWire
- 6 weeks ago - ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewsWire
- 6 weeks ago - ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewsWire
- 2 months ago - ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe - GlobeNewsWire
- 2 months ago - ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast - Benzinga